Phaseline

Targets › INHA

INHA (Inhibin alpha chain): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Infectious disease; next expected readout Apr 2028.

Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland. Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth,…. (UniProt, P05111)

Open in Phaseline: the race on INHA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Allergy and Infectious Diseases (NIAID)Isoniazid
Enoyl-[acyl-carrier-protein] reductase inhibitor
KATG, INHAPhase 2Tuberculous Meningitis; TuberculosisApr 2028

Conditions

Tuberculous Meningitis (1) Tuberculosis (1)

Modalities

small molecule (1)

Companies

National Institute of Allergy and Infectious Diseases (NIAID) (1)

Related targets

KATG (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.